Contents

24 May 2017
Vol 9, Issue 391
  • Research Articles

    • The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation

      The brain microenvironment triggers HER3-dependent de novo resistance to therapies targeting PI3K or HER2 in HER2-positive and/or PIK3CA-mutant breast cancer cells.

    • Bacterial colonization and succession in a newly opened hospital

      Patients share their microbiota with their rooms and with nursing staff, and this shapes the microbial ecology of the hospital environment.

    • Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy

      A multiplexed plasmonic assay analyzes circulating tumor-derived extracellular vesicles for detection of pancreatic ductal adenocarcinoma.

  • Report

    • The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis

      Analysis of ALS patient iPSC-derived motor neurons indicates that Src/c-Abl inhibitors may have potential for treating ALS.

  • Technical Comments

  • Editors' Choice

    • Nanomedicine goes to school

      Integration of engineering and immunological tools proposes design guidelines for nanoparticles that direct T cells toward specific phenotypes to control autoimmune disease.

    • Dive deep, stay focused!

      Noninvasive ultra-broadband optoacoustic mesoscopy skin imaging technology may provide objective assessment of skin disease.

About The Cover

Cover image expansion

ONLINE COVER No Escape for Brain Metastases. This image depicts the microenvironment of a breast cancer brain metastasis in a mouse model. The metastasis near the center of the image shows a collection of tortuous, irregular, and abnormally dilated blood vessels (superficial vessels, yellow; deeper vasculature, shades of red). By studying brain metastases and their microenvironment, Kodack et al. determined that the microenvironment directly contributed to drug resistance in metastatic breast cancer and identified a potential therapeutic strategy for treating these challenging tumors. [CREDIT: B. J. VAKOC, R. M. LANNING, A. S. NAM, R. K. JAIN/MGH]